reference/14945081

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14945081

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	338
issn	2305-5839 2305-5847
issueIdentifier	4
pageRange	338-338
publicationName	Annals of Translational Medicine
startingPage	338
bibliographicCitation	Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, Chen G, Liu X, Yang J, Zhang L, Chen J, Huang M, Tao M, Cheng G, Huang C, Zhou C, Zhang W, Zhao H, Sun Y. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med. 2021 Feb;9(4):338. PMID: 33708965; PMCID: PMC7944306.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aab00deda37eae405b28f2d1d15468dc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_15b21842d94c446eec334a3348862a8d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e400e5fb27acc644a14f5b71c4e5780 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc010e156a13806ae00368df24a7bacc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d82f3601aa6b65ee6687097216b7194 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c5618501723037a333d00963133191c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b265671698e4f80cb87ffb1c216e4d4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1d0be73ec2ea283bb5986460444f93a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f5a559dfe99e98336253e7c3faaeacc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98b0de0cf6408e365af368a48806b435 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_414a4dbce3504560f16a6be319929851 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b58abc222e0e3b8ace5459e72b6720a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e13de3e3479f8777eeb9e6879fa5f540 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f4385ffe6f2b7bc52fbc1a61037d516 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dabe8aecabff8136e2fd7d0d62c28df6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_445c654b648495d3b87dbcd7fd58361d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_771e96114be2b51a4884bab631c8786c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2099642ccadc286263e3629bfb747c4
date	202102
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC7944306 https://pubmed.ncbi.nlm.nih.gov/33708965 https://doi.org/10.21037/atm-20-8078
isPartOf	https://portal.issn.org/resource/ISSN/2305-5847 https://portal.issn.org/resource/ISSN/2305-5839 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/41941
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124

Showing number of triples: 1 to 43 of 43.